Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-30T21:11:31.525Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical Pharmacology of Antibiotics: The Use of Intraperitoneal Antibiotics to Treat Dialysis-Associated Peritonitis

Published online by Cambridge University Press:  02 January 2015

Terrill G. Washington  and
Mark Eggleston
Terrill G. Washington
Affiliation:
Howard University, College of Pharmacy and Pharmacal Sciences, Washington. DC
Mark Eggleston*
Affiliation:
Howard University, College of Pharmacy and Pharmacal Sciences, Washington. DC
*
P.O. Box 115, Woodbridge, VA 22191
Get access Rights & Permissions [Opens in a new window]

Extract

Peritoneal dialysis has been successfully used in treating patients with end stage renal disease (ESRD) for approximately 40 years. Peritoneal infections are a frequent consequence of this procedure which has diminished its acceptance by physicians and patients alike. Since the development of an improved access catheter and automated dialysate delivery devices, peritoneal analysis has been gaining widespread acceptance as an alternative to hemodialysis in the treatment of patients with ESRD. Despite the improvement in the peritoneal dialysis systems, peritonitis continues to be a major complication for adult and pediatric patients undergoing continuous ambulatory peritoneal dialysis (CAPD).:‘-’ Although most patients have from less than one to four peritonitis episodes per year, some patients have no episodes of' peritonitis or have a significantly high occurrence (greater than four episodes) of peritonitis. Several reports have indicated that two thirds of the total number of ‘peritonitis episodes is due to gram-positive bacteria. Gram-negative bacteria accounts for approximately 15% and fungal infections account for less than 5%.

Type
Special Section
Information
Infection Control & Hospital Epidemiology , Volume 9 , Issue 1 , January 1988 , pp. 37 - 39
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1988

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Mandell, GL, Douglas, RG, Bennett, JE. (eds): Principles and Practice of Infectious Diseases, ed 2. New York. Wiley Medical Publications, 1985, pp 487–488.Google Scholar
2.Lacke, C, et al: Twelve months experience with continuous ambulatory and intermittent peritoneal dialysis. Arch Intern Med 1981; 141:187–190.CrossRefGoogle ScholarPubMed
3.Audet, PR: Continuous ambulatory peritoneal dialysis: Information for a hospital pharmacist. Hasp Pharm 1984; 19:498–500.Google Scholar
4.Gokal, R, et al: Peritonitis in continuous ambulatory peritoneal dialysis. Lancet 1982; pp 1388–1391.CrossRefGoogle ScholarPubMed
5.Watson, AR, et al: Peritonitis during continuous ambulatory peritoneal dialysis in children. Can Med Assoc J 1986; 134:1019–1022.Google Scholar
6.Krothapalli, R, et al: Pseudomonas peritonitis and continuous ambulatory peritoneal dialysis. Arch Intern Med 1982; 142:1862–1863.Google Scholar
7.Kravitz, SP, et al: Successful treatment of Aspergillus peritonitis in a child undergoing continuous cycling peritoneal dialysis. Arch Intern Med 1986; 146:2061–2062.Google Scholar
8.Knight, KR, Polak, A: Laboratory diagnosis and oral treatment of CAPD peritonitis. Lancet 1982; pp 1301–1304.Google Scholar
9.Krothapalli, RK. Senkjian, HO, Ayus, JC: Efficacy of intravenous vancomycin in the treatment of gram-positive peritonitis in long term peritoneal dialysis. Am J Med 1983; 75:345–348.Google Scholar
10.Hale, DVC, et al: In vitro inactivation of aminoglycoside antibiotics by piperacillin and carbenicillin. Am J Clin Pathol 1980; 74:316–319.CrossRefGoogle ScholarPubMed
11.Gilman, AG, Goodman, LS, et al (eds): The Pharmacological Basis of Therapeutics, ed 7. New York, Macmillan Publishing Co, 1985, pp 1668–1713.Google Scholar